P&T COMMUNITY
 
MediMedia Managed Markets
Our
Other
Journal
Managed Care magazine
P&T Community, The Online Resource for P&T Decision Makers
Login / Register
Join Us  Facebook  Twitter  Linked In

 

News Categories

 

 

 

Report: Dyslipidemia Market Will Grow to $31 Billion in 2022, Driven by New Therapies

Statins will remain sales-leading drug class (August 20)

Decision Resources, a research and advisory firm located in Burlington, Mass., finds that the dyslipidemia market will grow to just over $31 billion in 2022, at an annual rate of 2 percent from 2012. The launch of antidyslipidemic agents from two novel drug classes — PCSK9 and CETP inhibitors — will be the primary drivers of market growth, off-setting the voracious “genericization” that will continue to affect the market through 2022.

The new report also finds that, despite continued generic erosion of Lipitor (atorvastatin, Pfizer) and the launch of generic versions of Crestor (AstraZeneca) and the ezetimibe franchise (Merck) — Zetia (ezetimibe), Vytorin (ezetimibe/simvastatin), Liptruzet (ezetimibe/atorvastatin) — statins will remain the sales-leading drug class through 2022.

“The failure of non-statin drugs to demonstrate a cardiovascular outcomes benefit above that of statin therapy in clinical trials has further cemented the first-line status of the statin class, and has eroded physicians’ willingness to address residual risk by normalizing non-LDL [low-density lipoprotein] lipids,” said analyst Pam Narang, MSc, PhD.

The report also notes that the result of the outcomes trial IMPROVE-IT for ezetimibe is the most highly anticipated near-term event in the dyslipidemia market. Positive data from this trial will have a significant effect on physician prescribing and will provide further validation of the hypothesis that low-density lipoprotein cholesterol (LDL-C) is the most modifiable dyslipidemia target, which will affect emerging LDL-C–lowering agents, such as the PCSK9 inhibitors. These agents will initially target patients with the highest risk. However, launching in a specific patient subpopulation with the intention of gaining a broader label is an established drug-development strategy.

Source: Decision Resources; August 20, 2013.

More stories